ICER report assesses value of hemophilia A therapies

The Institute for Clinical and Economic Review (ICER; MA, USA) has released an Evidence Report concerning the comparative clinical effectiveness and value of two therapies – valoctocogene roxaparvovec and emicizumab – for use in adults with hemophilia A who do not have factor VIII inhibitors. Hemophilia A is the most common form of hemophilia and affects one in every 5000 males. The condition arises from an inherited deficiency in factor VIII – an important factor in the clotting cascade – which results in individuals’ increased tendency to bleed. To manage the condition and reduce bleeding risks, individuals with hemophilia A...